A meta-analysis of tissue microbial biomarkers for recurrence and metastasis in multiple cancer types.

Background. Local recurrence and distant metastasis are the main causes of death in patients with cancer. Only considering species abundance changes when identifying markers of recurrence and metastasis in patients hinders finding solutions.Hypothesis. Consideration of microbial abundance changes and microbial interactions facilitates the identification of microbial markers of tumour recurrence and metastasis.Aim. This study aims to simultaneously consider microbial abundance changes and microbial interactions to identify microbial markers of recurrence and metastasis in multiple cancer types.Method. One thousand one hundred and six non-RM (patients without recurrence and metastasis within 3 years after initial surgery) tissue samples and 912 RM (patients with recurrence or metastasis within 3 years after initial surgery) tissue samples representing 11 cancer types were collected from The Cancer Genome Atlas (TCGA).Results. Tumour tissue bacterial composition differed significantly among 11 cancers. Among them, the tissue microbiome of four cancers, head and neck squamous cell carcinoma (HNSC), lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD) and uterine corpus endometrial carcinoma (UCEC), showed relatively good performance in predicting recurrence and metastasis in patients, with areas under the receiver operating characteristic curve (AUCs) of 0.78, 0.74, 0.91 and 0.93, respectively. Considering both species abundance changes and microbial interactions for the four cancers, a combination of nine genera (Niastella, Schlesneria, Thioalkalivibrio, Phaeobacter, Sphaerotilus, Thiomonas, Lawsonia, Actinobacillus and Spiroplasma) performed best in predicting patient survival.Conclusion. Taken together, our results imply that comprehensive consideration of microbial abundance changes and microbial interactions is helpful for mining bacterial markers that carry prognostic information.

[1]  Geng Tian,et al.  ICSDA: a multi-modal deep learning model to predict breast cancer recurrence and metastasis risk by integrating pathological, clinical and gene expression data , 2022, Briefings Bioinform..

[2]  K. Almstrup,et al.  The seminal plasma microbiome of men with testicular germ cell tumours described by small RNA sequencing , 2022, Andrology.

[3]  Geng Tian,et al.  A Systematic Framework for Identifying Prognostic Genes in the Tumor Microenvironment of Colon Cancer , 2022, Frontiers in Oncology.

[4]  Rui Hou,et al.  Predicting breast cancer recurrence and metastasis risk by integrating color and texture features of histopathological images and machine learning technologies , 2022, Comput. Biol. Medicine.

[5]  Huandong Yang,et al.  A multi-omics machine learning framework in predicting the survival of colorectal cancer patients , 2022, Comput. Biol. Medicine.

[6]  Yue Zhang,et al.  Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer , 2022, Cell.

[7]  D. Haller,et al.  Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders , 2022, Nature Reviews Gastroenterology & Hepatology.

[8]  Xiangxiang Zeng,et al.  A weighted bilinear neural collaborative filtering approach for drug repositioning , 2022, Briefings Bioinform..

[9]  Minghui Zhang,et al.  Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[10]  Zhang Yunxiang,et al.  Cervical Cancer Metastasis and Recurrence Risk Prediction Based on Deep Convolutional Neural Network , 2021, Current Bioinformatics.

[11]  A. Burgener,et al.  The Female Reproductive Tract Microbiome—Implications for Gynecologic Cancers and Personalized Medicine , 2021, Journal of personalized medicine.

[12]  C. Maher,et al.  Long noncoding RNAs in cancer metastasis , 2021, Nature Reviews Cancer.

[13]  Geng Tian,et al.  Evaluating DNA Methylation, Gene Expression, Somatic Mutation, and Their Combinations in Inferring Tumor Tissue-of-Origin , 2021, Frontiers in Cell and Developmental Biology.

[14]  F. Mégraud,et al.  Gastric Cancer: Advances in Carcinogenesis Research and New Therapeutic Strategies , 2021, International journal of molecular sciences.

[15]  T. Opriessnig,et al.  Review of methods for the detection of Lawsonia intracellularis infection in pigs , 2021, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[16]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[17]  C. Jin,et al.  Unexpected guests in the tumor microenvironment: microbiome in cancer , 2020, Protein & cell.

[18]  B. McCormick,et al.  Aging, Frailty, and the Microbiome: How Dysbiosis Influences Human Aging and Disease. , 2020, Gastroenterology.

[19]  Wan-Li Liu,et al.  Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16 , 2020, Gut.

[20]  H. Bai,et al.  Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer , 2020, Thoracic cancer.

[21]  Geng Tian,et al.  A machine learning framework to trace tumor tissue-of-origin of 13 types of cancer based on DNA somatic mutation. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[22]  D. Fouts,et al.  Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients , 2020, Gut microbes.

[23]  G. Michailidis,et al.  Gut microbiota dysbiosis and altered tryptophan catabolism contribute to autoimmunity in lupus-susceptible mice , 2020, Science Translational Medicine.

[24]  R. Aramayo,et al.  Rapid molecular evolution of Spiroplasma symbionts of Drosophila , 2020, bioRxiv.

[25]  Lanjuan Li,et al.  Clinical Significance of the Correlation between Changes in the Major Intestinal Bacteria Species and COVID-19 Severity , 2020, Engineering.

[26]  Noam Shental,et al.  The human tumor microbiome is composed of tumor type–specific intracellular bacteria , 2020, Science.

[27]  Geng Tian,et al.  Evaluating the Potential of T Cell Receptor Repertoires in Predicting the Prognosis of Resectable Non-Small Cell Lung Cancers , 2020, Molecular therapy. Methods & clinical development.

[28]  F. Shanahan,et al.  Mutagenesis by Microbe: the Role of the Microbiota in Shaping the Cancer Genome. , 2020, Trends in cancer.

[29]  Rob Knight,et al.  Microbiome analyses of blood and tissues suggest cancer diagnostic approach , 2020, Nature.

[30]  Crispin J. Miller,et al.  Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse , 2019, Nature Medicine.

[31]  Q. Deng,et al.  The characterization of lung microbiome in lung cancer patients with different clinicopathology. , 2019, American journal of cancer research.

[32]  B. Buchanan,et al.  Evolution of the thioredoxin system as a step enabling adaptation to oxidative stress. , 2019, Free radical biology & medicine.

[33]  X. Hua,et al.  The respiratory tract microbiome and its relationship to lung cancer and environmental exposures found in rural china , 2019, Environmental and molecular mutagenesis.

[34]  G. Muyzer,et al.  Diversity and Distribution of Sulfur Oxidation-Related Genes in Thioalkalivibrio, a Genus of Chemolithoautotrophic and Haloalkaliphilic Sulfur-Oxidizing Bacteria , 2019, Front. Microbiol..

[35]  Bhusan K. Kuntal,et al.  ‘NetShift’: a methodology for understanding ‘driver microbes’ from healthy and disease microbiome datasets , 2018, The ISME Journal.

[36]  I. Nookaew,et al.  PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin , 2018, Front. Microbiol..

[37]  Kathleen A Cronin,et al.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics , 2018, Cancer.

[38]  Donna Neuberg,et al.  Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer , 2017, Science.

[39]  Krishna R. Kalari,et al.  A comprehensive analysis of breast cancer microbiota and host gene expression , 2017, PloS one.

[40]  Xiao Han,et al.  Targeting the Thioredoxin System for Cancer Therapy. , 2017, Trends in pharmacological sciences.

[41]  J. Goedert,et al.  Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features , 2016, Genome Biology.

[42]  Yi Xin,et al.  Structural Change in Microbiota by a Probiotic Cocktail Enhances the Gut Barrier and Reduces Cancer via TLR2 Signaling in a Rat Model of Colon Cancer , 2016, Digestive Diseases and Sciences.

[43]  J. Dutkiewicz,et al.  Spiroplasma - an emerging arthropod-borne pathogen? , 2015, Annals of agricultural and environmental medicine : AAEM.

[44]  L. Mishra,et al.  EMT, CTCs and CSCs in tumor relapse and drug-resistance , 2015, Oncotarget.

[45]  Wendy S. Garrett,et al.  Cancer and the microbiota , 2015, Science.

[46]  Richard A. Moore,et al.  Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. , 2012, Genome research.

[47]  T. Shimizu,et al.  Macrophage activation and immunostimulating activity of Sphaerotilus natans and its slime fraction. , 1987, Chemical & pharmaceutical bulletin.